Should You Start Lokelma for This Patient?
Yes, you should strongly consider starting Lokelma (sodium zirconium cyclosilicate/SZC) for this patient on losartan with elevated potassium, but the decision depends critically on the actual potassium level and whether you want to maintain or optimize the losartan dose.
Key Decision Points
If Potassium is ≥5.1 mEq/L and You Want to Continue Losartan
Start Lokelma 10 g three times daily for 48 hours, then transition to 10 g once daily for maintenance 1. This approach is supported by robust phase 3 trial data showing:
- Mean potassium reduction of 1.1 mEq/L within 48 hours with the correction phase dosing 2
- 93% of patients maintained mean potassium ≤5.1 mEq/L over nearly one year of treatment 2
- Effective maintenance of normokalemia (3.8-5.1 mEq/L) with once-daily dosing 2
The primary advantage here is preventing RAAS inhibitor discontinuation—a critical consideration since losartan provides cardiovascular and renal protection that should not be sacrificed due to hyperkalemia 3, 4.
If Potassium is 5.0-5.5 mEq/L (Mild Hyperkalemia)
First address reversible factors:
- Review dietary potassium intake
- Check for constipation
- Assess for metabolic acidosis
- Eliminate unnecessary potassium-containing medications or supplements
If no reversible factors exist, initiate Lokelma 3. Patients with non-reversible risk factors have a 43% recurrence rate within 6-8 months if left untreated 3.
If Potassium is >6.5 mEq/L
Do NOT rely on Lokelma alone—it has delayed onset of action and is not approved for emergency treatment of life-threatening hyperkalemia 1. Use traditional acute therapies (calcium, insulin/glucose, salbutamol) first, then add Lokelma for sustained control 4, 5.
Practical Dosing Algorithm
Correction Phase (Days 1-2):
- 10 g orally three times daily mixed in water
- Separate from other oral medications by 2 hours 1
Maintenance Phase (Day 3 onward):
- Start 10 g once daily
- Check potassium weekly initially
- Titrate in 5 g increments at ≥1-week intervals based on potassium levels
- Maintenance range: 5 g every other day to 15 g daily 1
Critical Safety Considerations
Monitor for edema closely 1. Each 5 g dose contains approximately 400 mg sodium. This is particularly important if your patient has:
- Heart failure
- Significant renal impairment
- Sodium-sensitive hypertension
Increase diuretics as needed and counsel on dietary sodium restriction 1.
Watch for hypokalemia—discontinue or reduce dose if potassium drops below target range 1.
Avoid in severe constipation or bowel obstruction—Lokelma has not been studied in these conditions and may worsen gastrointestinal problems 1.
Why Lokelma Over Alternatives?
Compared to patiromer, SZC offers:
- Faster onset: Significant reductions within 1 hour, though not approved for acute use 2, 6
- More rapid correction: Achieves normokalemia within 48 hours vs. 7 hours for patiromer 2
- No drug interaction timing: While 2-hour separation is recommended, patiromer requires 3+ hours 2
The trade-off is higher edema risk (RR 2.92) with SZC versus higher constipation risk (RR 2.96) and hypokalemia (RR 1.46) with patiromer 7.
Common Pitfalls to Avoid
Don't discontinue losartan prematurely. The 2018 ESC consensus and 2025 European guidelines emphasize that RAASi discontinuation due to hyperkalemia or fear thereof offsets survival benefits 3, 4. Potassium binders enable continuation of guideline-directed therapy.
Don't wait for recurrent hyperkalemia to start treatment. If the patient has non-reversible risk factors (CKD, diabetes, on RAAS inhibitor), initiate preventive therapy after the first episode 3.
Don't use sodium polystyrene sulfonate (Kayexalate) as an alternative—it carries warnings for severe, potentially fatal gastrointestinal adverse events and has questionable efficacy 8, 5.
Bottom Line
For a patient on losartan 100 mg with hyperkalemia ≥5.1 mEq/L and no acute reversible causes, start Lokelma 10 g three times daily for 48 hours, then 10 g once daily, with weekly potassium monitoring and dose titration to maintain normokalemia while continuing the losartan 2, 3, 1.